ArticleThe Journal of clinical investigation2012

A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis.

Emmanuel Somm et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.